Single AAV intravenous dose achieved widespread CNS distribution and sustained correction of GCase activity in multiple brain regions CAMBRIDGE, Mass. , Oct. 20, 2021 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and

Reader Interactions

Leave A Reply